Back

Arrhythmic genotypes and risk of major ventricular arrhythmia in dilated cardiomyopathy: a multicentre japanese cohort

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Ventricular arrhythmias: epidemiology, prognosis, outcome Epidemiology, Prognosis, Outcome EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Mr Koshiro Kanaoka

National Cerebral & Cardiovascular Center, Suita (Japan)

6 More presentations in this session

Presentation thumbnail
Incidence and predictors of major arrhythmic events following acute myocarditis complicated by ventricular arrhythmias: a systematic review and meta-analysis.
Miss S. M'Rabet (Dijon, FR)
Abstract Slides Video
Presentation thumbnail
Predictors and outcomes of electrical storm in patients with sustained ventricular arrhythmias during acute myocardial infarction
Professor C. Guenancia (Dijon, FR)
Abstract Slides Video
Presentation thumbnail
Phenotypic clustering using cardiac magnetic resonance imaging differentiates genetic background and outcomes in dilated cardiomyopathy.
Doctor E. Goethals (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Prevalence and characteristics of the catecholamine induced QT prolongation syndrome
Professor J. Gourraud (Nantes, FR)
Abstract Slides Video
Presentation thumbnail
Pediatric electrical storm: clinical characteristics, management, and outcomes in a multicenter cohort
Doctor F. Alauze (Rennes, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Ventricular arrhythmias: epidemiology, prognosis, outcome

The Event

Event poster

EHRA 2026

12 April - 14 April 2026
You may be interested in
thumbnail
Congress Presentation
Advanced heart failure in patients with dilated cardiomyopathy and high-risk arrhythmic genotypes
thumbnail
Congress Presentation
Predicting risk and guiding therapy in biventricular/left-dominant arrhythmogenic cardiomyopathy
thumbnail
Congress Presentation
'The overlooked middle': patient with non-ischaemic cardiomyopathy and moderately impaired ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources